Standard of care treatment for stage IV, locally advanced, or unresectable human epidermal growth factor receptor 2 (HER2) negative esophageal adenocarcinomas and esophageal squamous cell carcinomas consists of chemo-immunotherapy (CI) [1,2]. The gene discussed is ERBB2; the disease is esophageal adenocarcinoma.